logo
  

TCR2 Therapeutics Reports Positive Interim Results From Ongoing Phase 1 Portion Of Gavo-cel Trial

TCR2 Therapeutics Inc. (TCRR) announced positive interim results from the ongoing phase 1 portion of the gavo-cel phase 1/2 clinical trial for mesothelin-expressing solid tumors. The company is very encouraged by the progression free survival and overall survival observed among patients with refractory mesothelioma treated so far with gavo-cel in the phase 1 trial. Gavo-cel was generally well tolerated with a manageable adverse event profile in the study.

The primary objectives of the phase 1 portion of the trial are to define the safety profile of gavo-cel in patients whose tumors overexpress mesothelin and to determine the recommended phase 2 dose. The company said the recommended phase 2 dose is being refined after identification of the maximum tolerated dose.

Alfonso Quintás-Cardama, Chief Medical Officer of TCR2, said: "Based on these data and the most recent patient experiencing a very mild safety profile at a cell dose of 3x108/m2, we believe the identification of the recommended phase 2 dose is close at hand."

Shares of TCR2 Therapeutics were up 4% in pre-market trade on Friday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Verizon Communications Inc. (VZ) said, on an adjusted basis, its third-quarter earnings per share rose 12.8 percent from a year ago. The company said its earnings were highlighted by revenue and customer growth as more than one in four Consumer wireless phone customers now have a 5G-capable device. The... While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of $3.55 to $3.6 per share and... Shares of Nestle SA were gaining around 4 percent in Swiss trading after the food and beverage giant on Wednesday raised its fiscal 2021 organic sales growth forecast after reporting higher sales in the first nine of the year. For the full year, the company now expects organic sales growth between 6 percent and 7 percent.
RELATED NEWS
Follow RTT